Dhoot Transmission’s shares were trading at Rs 1,174.95 on the NSE at 1:30 pm, down 2.13 % from the listing price of Rs 1,193.80. The stock had opened at a 37.06 % premium to its issue price of Rs 871 and later rose 39.23 % to Rs 1,212.70.
On the BSE, the share listed at Rs 1,200, which is a 37.77 % premium over the issue price. Investors saw the stock move in a similar upward trend on both exchanges.
Shivani Nyati, Head of Wealth at Swastika Investmart, noted that Dhoot Transmission’s strong revenue growth and growing exposure to the electric‑vehicle sector give a healthy long‑term outlook. She cautioned about high customer concentration and execution risks and advised a stop‑loss at Rs 1,100.
Dr Ravi Singh, Chief Research Officer at Master Capital Services, said investors who received allotments could book partial profits after the premium listing and hold the rest for the long term. Those who missed allotment could consider buying when the price falls.
The company’s Rs 3,067‑crore IPO attracted 74.21 times subscription on the final day of bidding. The price band was Rs 829‑871 per share.
Molbio Diagnostics also extended its post‑listing gains, trading at Rs 1,000 on the NSE, up 2.04 % from its listing price. The stock debuted at Rs 980 on both NSE and BSE, a 21.44 % premium over the issue price of Rs 807.
On the BSE, the share later surged 24.16 % to Rs 1,002.05, reflecting strong demand. Analysts highlighted the company’s leadership in molecular diagnostics and its expansion‑led growth strategy.
Nyati recommended a stop‑loss at Rs 900 and maintained a positive long‑term view, while Dr Singh urged investors to watch quarterly results to see how test‑kit volumes and new digital pathology businesses affect growth.
Molbio’s Rs 940‑crore IPO was subscribed 70.26 times on the final day of bidding. The price band ranged from Rs 768 to Rs 807 per share.
Overall, both stocks show promising fundamentals but investors should remain disciplined, monitor concentration risks, and consider long‑term horizons.